Abstract:Rationale:Reversing the hypoxic and immunosuppressive tumor microenvironment (TME) is crucial for treating malignant melanoma. Seeking a robust platform for the effective reversion of hypoxic and immunosuppressive TME may be an excellent solution to revolutionizing the current landscape of malignant melanoma treatment. Here, we demonstrated a transdermal and intravenous dual-administration paradigm. A tailor-made Ato/cabo@PEG-TK-PLGA NPs were administrated transdermally to melanoma with the help of a gel spray containing a skin-penetrating material borneol. Nanoparticles encased Ato and cabo were released and thereby reversed the hypoxic and immunosuppressive tumor microenvironment (TME).Methods:Ato/cabo@PEG-TK-PLGA NPs were synthesized through a self-assembly emulsion process, and the transdermal ability was assessed using Franz diffusion cell assembly. The inhibition effect on cell respiration was measured by OCR, ATP, and pO2 detection and in vivo photoacoustic (PA) imaging. The reversing of the immunosuppressive was detected through flow cytometry analysis of MDSCs and T cells. At last, the in vivo anti-tumor efficacy and histopathology, immunohistochemical analysis and safety detection were performed using tumor-bearing mice.Results:The transdermally administrated Ato/cabo@PEG-TK-PLGA NPs successfully spread to the skin surface of melanoma and then entered deep inside the tumor with the help of a gel spray and a skin puncturing material borneol. Atovaquone (Ato, a mitochondrial-respiration inhibitor) and cabozantinib (cabo, a MDSCs eliminator) were concurrently released in response to the intratumorally overexpressed H2O2. The released Ato and cabo respectively reversed the hypoxic and immunosuppressive TME. The reversed hypoxic TME offered sufficient O2 for the intravenously administrated indocyanine green (ICG, an FDA-approved photosensitizer) to produce adequate amount of ROS. In contrast, the reversed immunosuppressive TME conferred amplified systemic immune responses.Conclusion:Taken together, we developed a transdermal and intravenous dual-administration paradigm, which effectively reversed the hypoxic and immunosuppressive tumor microenvironment in the treatment of the malignant melanoma. We believe our study will open a new path for the effective elimination of the primary tumors and the real-time control of tumor metastasis.

Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma

Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma

Combined immunochemotherapy achieving targeted co-delivery of chlorogenic acid and doxorubicin by sialic acid-modified liposomes enhances anti-cancer efficacy

Optimizing Multistep Delivery of PEGylated Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand-Toxin Conjugates for Improved Antitumor Activities.

Improved melanoma suppression with target-delivered TRAIL and PaclitaxSel by a multifunctional nanocarrier.

Recent Advances in Targeted Nanoparticles Drug Delivery to Melanoma

Towards combinatorial targeted therapy in melanoma: From pre-clinical evidence to clinical application (Review)

Exploiting in Situ Antigen Generation and Immune Modulation to Enhance Chemotherapy Response in Advanced Melanoma: A Combination Nanomedicine Approach.

Codelivery of afuresertib and celecoxib by IL4RPep-1-targeting nanoparticles for effective treatment against melanoma

Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges

Low Doses of Niclosamide and Quinacrine Combination Yields Synergistic Effect in Melanoma Via Activating Autophagy-Mediated P53-Dependent Apoptosis.

TRIAL-based Combination Therapies in Cancers

Multifunctional Nanoparticle Approach for Targeting Melanoma

Advances in Understanding Drug Resistance Mechanisms and Innovative Clinical Treatments for Melanoma

Synergistic Induction of Tumor Cell Apoptosis by Death Receptor Antibody and Chemotherapy Agent Through JNK/p38 and Mitochondrial Death Pathway

Defeating Melanoma Through a Nano-Enabled Revision of Hypoxic and Immunosuppressive Tumor Microenvironment.

Real-world Efficacy and Safety of Axitinib in Combination with Anti-Programmed Cell Death-1 Antibody for Advanced Mucosal Melanoma

Targeted nanoscale drug delivery systems for melanoma therapy

Enhancement of Anti-Tumor Properties of Trail by Targeted Delivery to the Tumor Neovasculature

Advances in Targeted Therapies and Combination Approaches for Melanoma: A Comprehensive Review

Engineering an Anthrax Toxin inspired protein-ligand for Nanoparticle-Mediated Treatment of Malignant Melanoma